Current role
Biotechnology · Healthcare
CFO, CEO
2018-01-01–present
Thomas A. Fitzgerald
Equibles does not estimate personal net worth.
About Thomas A. Fitzgerald
Thomas A. Fitzgerald is recorded as CEO at Transcode Therapeutics, Inc. (RNAZ) since January 13, 2024 and CFO at Transcode Therapeutics, Inc. (RNAZ). The newest filing on record that lists Thomas A. Fitzgerald as CFO at Transcode Therapeutics, Inc. (RNAZ) is dated June 2, 2026. Transcode Therapeutics, Inc. reported in an 8-K filed September 11, 2026 that Thomas A. Fitzgerald resigned as member of the Board of Directors, effective September 9, 2026. Transcode Therapeutics, Inc. reported in an 8-K filed September 11, 2026 that Thomas A. Fitzgerald resigned as Chief Financial Officer, effective September 9, 2026. Transcode Therapeutics, Inc. reported in an 8-K filed October 8, 2025 that Thomas A. Fitzgerald resigned as Interim Chief Executive Officer. Equibles holds 5 filed executive changes naming Thomas A. Fitzgerald; each is listed under recent activity with its source filing. The proxy statement of Transcode Therapeutics, Inc. reports total compensation of $1,069,615 for Thomas A. Fitzgerald in fiscal 2025, including a base salary of $480,000. Disclosed compensation is on record for 6 fiscal years. Transcode Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Transcode Therapeutics, Inc. includes Philippe Calais (CEO), Philippe P. Calais (CEO and Board Member), John Tattory (CFO) and 6 others.
“On September 10, 2026, TransCode Therapeutics, Inc. (the “Company”) announced that Thomas A. Fitzgerald, M.B.A. had resigned as Chief Financial Officer, principal financial officer and principal accounting officer of the Company, and as a member of the Board of Directors of the Company (the “Board”), as well as from all other officer and director positions he held with the Company and any of its subsidiaries, in each case effective as of September 9, 2026 (the “Separation Date”).”
“On September 10, 2026, TransCode Therapeutics, Inc. (the “Company”) announced that Thomas A. Fitzgerald, M.B.A. had resigned as Chief Financial Officer, principal financial officer and principal accounting officer of the Company, and as a member of the Board of Directors of the Company (the “Board”), as well as from all other officer and director positions he held with the Company and any of its subsidiaries, in each case effective as of September 9, 2026 (the “Separation Date”).”
Affiliation history
-
Current
2024-01-13–present
-
Current
Start not stated–present
Last confirmed June 2, 2026
-
2024-01-13–2025-10-08
-
2018-01-01–2026-09-09
Company network
Leadership on record at Transcode Therapeutics, Inc.
- Philippe Calais CEO
- Philippe P. Calais CEO, Board Member
- John Tattory CFO
- Zdravka Medarova CTO
- Elizabeth Czerepak Board Member
- Erik Manting Board Member
- Jack E. Stover Board Member
- Jack Stover Board Member
- Magda Marquet Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Transcode Therapeutics, Inc. (RNAZ) | Vice President, Chief Financial Officer, and former interim Chief Executive Officer | $480,000 | $1,069,615 |
| 2024 | Transcode Therapeutics, Inc. (RNAZ) | Interim Chief Executive Officer, Vice President and Chief Financial Officer | $255,076 | $956,966 |
| 2023 | Transcode Therapeutics, Inc. (RNAZ) | Interim Chief Executive Officer, Vice President and Chief Financial Officer | $358,138 | $426,862 |
| 2022 | Transcode Therapeutics, Inc. (RNAZ) | Interim Chief Executive Officer, Vice President and Chief Financial Officer | $371,000 | $560,701 |
| 2021 | Transcode Therapeutics, Inc. (RNAZ) | Vice President and Chief Financial Officer | $180,000 | $317,613 |
| 2020 | Transcode Therapeutics, Inc. (RNAZ) | Vice President and Chief Financial Officer | — | $15,386 |